EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low‐ and Lower‐Middle‐Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks

Deepak Bansal iD, Swati Chandel, Rekha Hans, Richa Jain, Swetha Palla iD, Srinivasan Peyam, Nitin J Peters iD, Prema Menon, Renu Madan, Rakesh Kapoor, Divjot Singh Lamba iD, Radhika Srinivasan iD und 6 weitere

Pediatric Blood & Cancer · 2026-08 · 73 (8)

DOI: 10.1002/1545-5017.70388 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.05.2026. Verfasst von Deepak Bansal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, C…. Hauptthemen laut MEDLINE: Neuroblastoma, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim was to enhance access to autologous stem cell transplant (ASCT) for high‐risk neuroblastoma in a public hospital in a lower‐middle‐income country, while ensuring safety.

Methods

Data from a single center were analyzed in this ambispective, observational study spanning 12 years (2012–2023). The adaptations included performing ASCT in isolation rooms within the general ward, storing stem cells at 2°C–6°C without cryopreservation for 7 days, utilizing plerixafor for stem cell mobilization, no central lines, minimizing venipunctures for sampling, no antibacterial/antifungal/antiviral prophylaxis, administering pegylated‐G‐CSF on Day +4, avoiding platelet transfusion for asymptomatic thrombocytopenia, prednisolone for preventing engraftment syndrome, and early discharge upon rising white cell count and monocytosis.

Results

Seventy‐three patients were treated on the backbone of the high‐risk neuroblastoma study‐1 of SIOP‐Europe (SIOPEN). The median age was 38 months. Sixty‐six (90.4%) patients had Stage 4 disease. A regimen of busulfan+melphalan was administered to 62 (84.9%) patients. Median CD34 cell count and stem cell viability were 5.2 × 10 6 /kg and 91.5%. The median hospital stay was 20 days. At discharge, the median absolute neutrophil and platelet counts were 0.60 × 10 9 /L and 19 × 10 9 /L. After 2017, there was a reduction in the number of aphereses ( p < 0.001), blood transfusions ( p = 0.003), amphotericin ( p = 0.012), and venipunctures ( p = 0.045). Forty (54.8%) patients died; relapse: 33 (82.5%); progressive disease: five (12.5%); and treatment‐related mortality: two (5%). There was no case of engraftment failure. The median follow‐up for surviving patients was 55.3 months. Five‐year overall survival (OS) and event‐free survival (EFS) were 34.6% ± 6.6% and 27% ± 5.8%. Survival was comparable to our historical cohort of 28 patients treated without ASCT (4‐year EFS: 29.3%; 4‐year OS: 29.3%).

Conclusion

In our cohort, the incorporation of ASCT into multimodality therapy was feasible with resource‐adapted strategies; however, this did not translate into a meaningful improvement in survival outcomes when compared with our historical non‐transplant cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaHematopoietic Stem Cell TransplantationTransplantation ConditioningHumansFemaleMaleTransplantation, AutologousChild, PreschoolInfantChildDeveloping CountriesResource-Limited SettingsAdolescent

Stichwörter der Autor:innen

LMICautologous stem cell rescuecryopreservationneuroblastomaplerixaforsurvival

Autor:innen und Institutionen

  • Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Pediatric Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Cytology and Gynecological Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Deepak Bansal, Swetha Palla, Nitin J Peters, Divjot Singh Lamba, Radhika Srinivasan, Ratti Ram Sharma

Zitieren

APA

Bansal, D., Chandel, S., Hans, R., Jain, R., Palla, S., Peyam, S., Peters, N. J., Menon, P., Madan, R., Kapoor, R., Lamba, D. S., Srinivasan, R., Kakkar, N., Kumar, R., Bhattacharya, A., Das, R., Sharma, R. R., & Trehan, A. (2026). Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low‐ and Lower‐Middle‐Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70388

Vancouver

Bansal D, Chandel S, Hans R, Jain R, Palla S, Peyam S, et al. Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low‐ and Lower‐Middle‐Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70388

BibTeX
@article{Bansal2026,
  author = {Bansal, Deepak and Chandel, Swati and Hans, Rekha and Jain, Richa and Palla, Swetha and Peyam, Srinivasan and Peters, Nitin J and Menon, Prema and Madan, Renu and Kapoor, Rakesh and Lamba, Divjot Singh and Srinivasan, Radhika and Kakkar, Nandita and Kumar, Rajender and Bhattacharya, Anish and Das, Reena and Sharma, Ratti Ram and Trehan, Amita},
  title = {Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low‐ and Lower‐Middle‐Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {8},
  doi = {10.1002/1545-5017.70388}
}
Kostenlos starten →